Payment overview · 2025
General Payments
$2,906.84
113 reported records · 27 companies
Healthcare provider profile · identity verified
Pavan K Yerramsetty, M.D.
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Pain Medicine · RALEIGH, NC · NPI 1245269513
Verified facts
What the public records show
CMS Open Payments records show Pavan K Yerramsetty, M.D. received $2,906.84 in general payments during 2025 across 113 reported records.
ABBVIE INC. accounted for 19.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 34 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ubrelvy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Ubrelvy by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $571.91 | 19.7% | 25 | 2025 |
| Averitas Pharma Inc. | Unresolved — no canonical attribution shown | $368.58 | 12.7% | 11 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $327.63 | 11.3% | 7 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $190.23 | 6.5% | 2 | 2025 |
| BIOTRONIK NRO, Inc. | Unresolved — no canonical attribution shown | $162.36 | 5.6% | 2 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $137.84 | 4.7% | 6 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $102.48 | 3.5% | 5 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $100.51 | 3.5% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $82.47 | 2.8% | 5 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $80.08 | 2.8% | 3 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $75.69 | 2.6% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $73.79 | 2.5% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $72.13 | 2.5% | 5 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $70.66 | 2.4% | 4 | 2025 |
| Neurelis, Inc. |
Neurelis, Inc. exact · evidence 2025-02-20 |
$60.20 | 2.1% | 4 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $57.27 | 2.0% | 3 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $55.64 | 1.9% | 3 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $48.48 | 1.7% | 2 | 2025 |
| Merz Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $44.94 | 1.6% | 3 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$43.86 | 1.5% | 2 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $39.88 | 1.4% | 2 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $32.73 | 1.1% | 2 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $31.26 | 1.1% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $22.71 | 0.8% | 1 | 2025 |
| Invivyd Inc | Unresolved — no canonical attribution shown | $20.02 | 0.7% | 1 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $17.48 | 0.6% | 1 | 2025 |
| Impel Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $16.01 | 0.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,906.84 | 113 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $489.27 | 21 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $382.61 | 20 | 2025 |
Source payment records
|
|||||
| QUTENZA Normalized: qutenza |
Drug | Averitas Pharma Inc. | $368.58 | 11 | 2025 |
Source payment records
|
|||||
| WaveWriter Alpha Prime 16 Normalized: wavewriter alpha prime 16 |
Device | Boston Scientific Corporation | $190.23 | 2 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $189.64 | 6 | 2025 |
Source payment records
|
|||||
| Prospera Normalized: prospera |
Device | BIOTRONIK NRO, Inc. | $162.36 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $137.99 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $137.84 | 6 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $100.51 | 4 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $82.47 | 5 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $82.47 | 5 | 2025 |
Source payment records
|
|||||
| ETERNA Normalized: eterna |
Device | Abbott Laboratories | $80.08 | 3 | 2025 |
Source payment records
|
|||||
| Belbuca Normalized: belbuca |
Drug | Collegium Pharmaceutical, Inc. | $79.96 | 4 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $75.69 | 4 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $73.79 | 4 | 2025 |
Source payment records
|
|||||
| LEQEMBI Normalized: leqembi |
Drug | Biogen, Inc., Eisai Inc. | $72.61 | 4 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $70.66 | 4 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $60.79 | 3 | 2025 |
Source payment records
|
|||||
| VALTOCO Normalized: valtoco |
Drug | Neurelis, Inc. | $60.20 | 4 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $55.07 | 4 | 2025 |
Source payment records
|
|||||
| BREKIYA Normalized: brekiya |
Drug | Amneal Pharmaceuticals LLC | $48.48 | 2 | 2025 |
Source payment records
|
|||||
| Xeomin Normalized: xeomin |
Biological | Merz Pharmaceuticals, LLC | $44.94 | 3 | 2025 |
Source payment records
|
|||||
| INCEPTIV Normalized: inceptiv |
Device | Medtronic, Inc. | $43.86 | 2 | 2025 |
Source payment records
|
|||||
| AMYVID Normalized: amyvid |
Drug | Lilly USA, LLC | $41.07 | 3 | 2025 |
Source payment records
|
|||||
| AJOVY Normalized: ajovy |
Biological | Teva Pharmaceuticals USA, Inc. | $39.77 | 2 | 2025 |
Source payment records
|
|||||
| Rystiggo Normalized: rystiggo |
Drug | UCB, Inc. | $31.26 | 1 | 2025 |
Source payment records
|
|||||
| INBRIJA Normalized: inbrija |
Drug | Merz Pharmaceuticals, LLC | $28.34 | 2 | 2025 |
Source payment records
|
|||||
| RELISTOR Normalized: relistor |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $22.71 | 1 | 2025 |
Source payment records
|
|||||
| XTAMPZA Normalized: xtampza |
Drug | Collegium Pharmaceutical, Inc. | $22.52 | 1 | 2025 |
Source payment records
|
|||||
| PEMGARDA Normalized: pemgarda |
Biological | Invivyd Inc | $20.02 | 1 | 2025 |
Source payment records
|
|||||
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $17.48 | 1 | 2025 |
Source payment records
|
|||||
| EMGALITY Normalized: emgality |
Drug | Lilly USA, LLC | $17.06 | 1 | 2025 |
Source payment records
|
|||||
| TRUDHESA Normalized: trudhesa |
Drug | Impel Pharmaceuticals LLC | $16.01 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $15.87 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 460 | 143 |
| Pregabalin | Pregabalin | 287 | 69 |
| Tramadol Hcl | Tramadol Hcl | 269 | 75 |
| Donepezil Hcl | Donepezil Hcl | 223 | 67 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 150 | 52 |
| Buprenorphine | Buprenorphine | 140 | 29 |
| Memantine Hcl | Memantine Hcl | 118 | 36 |
| Amitriptyline Hcl | Amitriptyline Hcl | 101 | 38 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 98 | 22 |
| Tizanidine Hcl | Tizanidine Hcl | 94 | 20 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 84 | 26 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 80 | 30 |
| Meloxicam | Meloxicam | 73 | 36 |
| Baclofen | Baclofen | 63 | 19 |
| Levetiracetam | Levetiracetam | 62 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 61 | 22 |
| Oxycodone Hcl | Oxycodone Hcl | 57 | 19 |
| Ropinirole Hcl | Ropinirole Hcl | 54 | 12 |
| Rizatriptan | Rizatriptan Benzoate | 50 | 21 |
| Trazodone Hcl | Trazodone Hcl | 50 | 13 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 49 | suppressed |
| Celecoxib | Celecoxib | 47 | 13 |
| Clonazepam | Clonazepam | 46 | 11 |
| Carbamazepine Er | Carbamazepine | 43 | 11 |
| Topiramate | Topiramate | 43 | 14 |
| Lacosamide | Lacosamide | 38 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 34 | 13 |
| Primidone | Primidone | 32 | 15 |
| Diazepam | Diazepam | 31 | 18 |
| Quetiapine Fumarate | Quetiapine Fumarate | 31 | suppressed |
| Methylprednisolone | Methylprednisolone | 30 | 25 |
| Ajovy Autoinjector | Fremanezumab-Vfrm | 26 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 26 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 26 | suppressed |
| Carisoprodol | Carisoprodol | 25 | suppressed |
| Lorazepam | Lorazepam | 25 | suppressed |
| Alprazolam | Alprazolam | 22 | suppressed |
| Riluzole | Riluzole | 22 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 21 | suppressed |
| Fentanyl | Fentanyl | 21 | 13 |
| Lamotrigine | Lamotrigine | 21 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 21 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 20 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 20 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 20 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 17 | suppressed |
| Methadone Hcl | Methadone Hcl | 16 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 16 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 15 | suppressed |
| Ondansetron Odt | Ondansetron | 15 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 15 | suppressed |
| Ubrelvy | Ubrogepant | 15 | suppressed |
| Lamictal | Lamotrigine | 13 | suppressed |
| Prednisone | Prednisone | 13 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 13 | suppressed |
| Zonisamide | Zonisamide | 13 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 12 | suppressed |
| Atorvastatin Calcium | Atorvastatin Calcium | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
| Tegretol Xr | Carbamazepine | 11 | suppressed |
| Temazepam | Temazepam | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,906.84 · 113 records | ABBVIE INC. | ACTHAR, AJOVY, AMYVID, AUSTEDO XR, BOTOX, BREKIYA, Belbuca, EMGALITY, ETERNA, INBRIJA, INCEPTIV, INGREZZA, KISUNLA, LEQEMBI, NURTEC ODT, PEMGARDA, Prospera, QULIPTA, QUTENZA, RELISTOR, REXULTI, Rystiggo, Symbravo, TRUDHESA, UBRELVY, ULTOMIRIS, UPLIZNA, VALTOCO, VYEPTI, VYVGART HYTRULO, WaveWriter Alpha Prime 16, XTAMPZA, Xeomin, ZAVZPRET | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ubrelvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error